Cognition's zervimesine slowed DLB hallucinations 89%, FDA calls it approvable
New Phase 2 SHIMMER data due at AAIC in July extend a placebo-controlled result that already secured FDA alignment on a Phase 3 psychosis trial for a disease with no approved therapy.
Executive Summary
- Completed Phase 2 data already show zervimesine slowing the progression of hallucinations and delusions in dementia with Lewy bodies versus placebo, and the FDA has agreed that reversing DLB psychosis is an approvable outcome.
- A July conference presentation will break out the hallucination and delusion components of that result, adding granularity to a dataset that has already shaped a Phase 3 design agreement with the FDA.
- No drug is approved for DLB psychosis today, leaving off-label antipsychotics as the only recourse, which is the unmet-need backdrop the FDA's approvability stance and the coming Phase 3 program address.
- Zervimesine's sigma-2 receptor mechanism has no third-party competitor in this indication, and the nearest comparator development activity is Cognition's own Alzheimer's program on the same target.
The disclosure
Cognition Therapeutics, Inc. said on June 24, 2026 that the FDA had reached alignment on key aspects of a pivotal trial design for zervimesine in dementia with Lewy bodies (DLB) psychosis, agreeing that reversing psychosis symptoms in this population could support a New Drug Application. The registrational program is expected to start in mid-2027, testing 100 mg once-daily oral zervimesine against placebo over nine months in DLB patients experiencing hallucinations and delusions, with the Neuropsychiatric Inventory (NPI) proposed as a novel primary endpoint. Chief medical officer Anthony Caggiano said the company reached 'an important agreement with the FDA that DLB psychosis could be an approvable outcome and that key aspects of our registrational trial design are appropriate and supportive of a NDA'. CognitionCognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB ...Jun 24, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The Phase 2 basis
That alignment builds on the completed Phase 2 COG1201 'SHIMMER' trial (NCT05225415), a 130-patient, placebo-controlled study in adults with mild-to-moderate DLB that finished enrollment in November 2024. Cognition said a recent analysis of the SHIMMER results showed zervimesine slowed progression of hallucinations and delusions by 89% versus placebo as measured by the NPI. The trial's registered primary endpoint was safety and tolerability, tracked as treatment-emergent adverse events across the 100 mg, 300 mg, and placebo arms, each with 42 to 44 participants at risk. The NPI-12 total score and eight other measures, including cognition (MoCA), sleepiness (ESS), and motor function (MDS-UPDRS Part III), were registered as secondary endpoints. NCT05225415+1Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB ...Jun 24, 2026
What July adds
The AAIC presentation will break out zervimesine's effect on the hallucination and delusion components of the NPI specifically, rather than the composite score already disclosed. Because the underlying trial completed in November 2024 and posted results to ClinicalTrials.gov in March 2026, the July event is a more granular look at data already in hand, not a new controlled comparison. The trial's registry history shows one enrollment increase from 120 to 130 participants and a primary completion date shift from April to November 2024, both logged in a single May 2024 amendment ahead of completion. Cognition+1Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB ...Jun 24, 2026Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesNCT05225415
The competitive frame
Sigma-2 receptor antagonism has a limited footprint in DLB: Cognition's own Phase 2 CT1812 trial in early Alzheimer's disease is the nearest direct comparator sharing the target and modality, and no third-party sponsor has an active trial combining the sigma-2 receptor target with DLB psychosis. Other DLB-focused compounds in development, including neflamapimod, fosgonimeton, and nelotanserin, work through different targets and represent modality precedent rather than mechanism competition. Approved DLB therapies such as donepezil and galantamine address cognition through acetylcholinesterase inhibition and were not designed for psychosis, underscoring that no approved drug currently targets the hallucination and delusion symptoms zervimesine is being developed against.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.